belapectin
belapectin: developed by 1 company · 2 clinical trials tracked.
belapectin evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could belapectin → GALT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| GALECTIN THERAPEUTICS INC (GALT) Hepatic Impairment; Prevention of Esophageal Varices | Phase 1 |
Clinical Trials (2)
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Primary endpoint: Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to Placebo
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
Primary endpoint: To Assess the PK AUC0-∞ of Belapectin Following a Single IV Dose of Belapectin in Subjects With Mild, Moderate, or Severe Hepatic Impairment, Compared to Healthy Subjects With Normal Hepatic Function.
Frequently asked questions
Who is developing belapectin?
belapectin is being developed by GALECTIN THERAPEUTICS INC.
How many clinical trials involve belapectin?
BioSniper tracks 2 clinical trials involving belapectin.